Innovent Biologics (HK:1801) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Innovent Biologics has entered into an exclusive global license agreement with Roche for the development and commercialization of its novel DLL3-targeted antibody drug conjugate, IBI3009. The deal includes an upfront payment of $80 million to Innovent, with potential milestone payments reaching $1 billion, alongside tiered royalties. This partnership aims to provide new treatment options for advanced small cell lung cancer.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
